BAMF
ACAD icon

BI Asset Management Fondsmaeglerselskab’s Acadia Pharmaceuticals ACAD Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,186
Closed -$100K – 722
2023
Q4 		$100K Buy
+3,186
New +$76.1K ﹤0.01% 682
2020
Q1 		– Sell
-13,829
Closed -$592K – 316
2019
Q4 		$592K Buy
+13,829
New +$602K 0.03% 254

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's ACAD Position: Q1 2024 in Review

BI Asset Management Fondsmaeglerselskab sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 3,186 shares — an estimated $100K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in ACAD in Q4 2019 and held it in 2 quarters. The position peaked at $592K in Q4 2019. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 3,186 Acadia Pharmaceuticals shares in Q1 2024, an estimated $100K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's Acadia Pharmaceuticals position peaked at $592K in Q4 2019.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q1 2024, filed 3 May 2024.